Subject(s)
Pilonidal Sinus/diagnostic imaging , Pilonidal Sinus/epidemiology , Spondylitis, Ankylosing/epidemiology , Adult , Chi-Square Distribution , Cohort Studies , Comorbidity , Conservative Treatment , Female , France , Humans , Male , Middle Aged , Orthopedic Procedures/methods , Pilonidal Sinus/therapy , Prevalence , Prognosis , Retrospective Studies , Risk Assessment , Sacrococcygeal Region , Spondylitis, Ankylosing/diagnostic imaging , Spondylitis, Ankylosing/therapy , Treatment OutcomeABSTRACT
BACKGROUND/AIMS: Proton-pump inhibitor and ranitidine bismuth citrate-based triple regimens are the two recommended first line treatments for the eradication of Helicobacter pylori. We aimed to compare the effectiveness and tolerability of these two treatments in a prospective, multicentric, randomized study. MATERIALS AND METHODS: Patients with dyspeptic complaints were recruited from 15 study centers. Presence of Helicobacter pylori was investigated by both histology and rapid urease test. The patients were randomized to either ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=149) or lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=130) treatment arm for 14 days. Adverse events have been recorded during the treatment phase. A 13 C urea breath test was performed 6 weeks after termination of treatment to assess the efficacy of the therapy. Eradication rate was calculated by intention-to-treat and per-protocol analysis. RESULTS: Two hundred seventy-nine patients (123 male, 156 female) were eligible for randomization. In per-protocol analysis (n=247), Helicobacter pylori was eradicated with ranitidine bismuth citrate- and lansoprazole-based regimens in 74,6% and 69,2% of cases, respectively (p>0,05). Intention-to-treat analysis (n=279) revealed that eradication rates were 65,1% and 63,6% in ranitidine bismuth citrate and in lansoprazole-based regimens, respectively (p>0,05). Both regimes were well-tolerated, and no serious adverse event was observed during the study. CONCLUSION: Ranitidine bismuth citrate-based regimen is at least as effective and tolerable as the classical proton-pump inhibitor-based regimen, but none of the therapies could achieve the recommendable eradication rate.
Subject(s)
Amoxicillin/administration & dosage , Bismuth/administration & dosage , Dyspepsia/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Lansoprazole/administration & dosage , Ranitidine/analogs & derivatives , Adolescent , Adult , Aged , Amoxicillin/adverse effects , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Bismuth/adverse effects , Clarithromycin/administration & dosage , Clarithromycin/adverse effects , Drug Administration Schedule , Drug Therapy, Combination , Dyspepsia/microbiology , Endoscopy, Digestive System , Female , Helicobacter Infections/diagnosis , Histamine H2 Antagonists/administration & dosage , Histamine H2 Antagonists/adverse effects , Humans , Lansoprazole/adverse effects , Male , Middle Aged , Prospective Studies , Proton Pump Inhibitors/administration & dosage , Proton Pump Inhibitors/adverse effects , Ranitidine/administration & dosage , Ranitidine/adverse effects , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. METHODS: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib. RESULTS: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically. CONCLUSION: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
Subject(s)
Antineoplastic Agents/administration & dosage , Boronic Acids/administration & dosage , POEMS Syndrome/drug therapy , Pyrazines/administration & dosage , Bortezomib , Glycoproteins/blood , Humans , Male , POEMS Syndrome/blood , Remission InductionABSTRACT
OBJECTIVE: Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme cyclooxygenase-2, is a novel anti-inflammatory drug with minimal gastrointestinal toxic effects while retaining anti-inflammatory efficacy. Our aim was to assess the potential effects of celecoxib on gastric permeability in comparison with placebo and ibuprofen. DESIGN: We conducted a prospective, double-blind, cross-over study. SETTING: This study is carried out at Marmara University Hospital. PARTICIPANTS: Twenty-five healthy subjects entered the study but 19 subjects completed the treatment. INTERVENTION: Subjects were randomized to celecoxib 100 mg twice daily, ibuprofen 600 mg twice daily or placebo for 7 days in pre-defined sequences. Treatments were separated by a 7 day washout period. MAIN OUTCOME MEASURE: Gastric permeability was assessed by measuring urinary excretion of sucrose spectrophotometrically. RESULTS: Ibuprofen 600 mg twice daily produced greater increases in gastric permeability compared with placebo or celecoxib (geometric mean of urinary sucrose recovery was 59.15, 32.65 and 33.11 mg/h for ibuprofen, placebo and celecoxib, respectively) (P < 0.001). Celecoxib was generally better tolerated than ibuprofen. CONCLUSIONS: When compared with ibuprofen, celecoxib 100 mg twice daily has no significant effect on gastric mucosa in healthy subjects.
